Ignite Creation Date:
2024-05-06 @ 3:02 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04501250
Status:
COMPLETED
Last Update Posted:
2020-08-06
First Post:
2020-08-03
Brief Title:
Comparative Study of Rinsulin NPH Suspension for Subcutaneous Administration 100 IUml GEROPHARM LLC Russia and Humulin NPH Suspension for Subcutaneous Administration 100 IUml Lilly France France Using the Euglycemic Hyperinsulinemic Clamp Method
Sponsor:
Geropharm
Organization:
Geropharm
Study Overview
Official Title:
A Double-blinded Randomized Comparative Crossover Pharmacokinetics Study of Rinsulin NPH Suspension for Subcutaneous Administration 100 IUml GEROPHARM LLC Russia and Humulin NPH Suspension for Subcutaneous Administration 100 IUml Lilly France France Using Method of Euglycemic Hyperinsulinemic Clamp on Healthy Volunteers
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Сomparative pharmacokinetic study of Rinsulin NPH suspension for subcutaneous administration 100 IUml GEROPHARM LLC Russia and Humulin NPH suspension for subcutaneous administration 100 IUml Lilly France France using the euglycemic hyperinsulinemic clamp
Detailed Description:
A double-blinded randomized comparative crossover pharmacokinetics study of Rinsulin NPH suspension for subcutaneous administration 100 IUml GEROPHARM LLC Russia and Humulin NPH suspension for subcutaneous administration 100 IUml Lilly France France using method of euglycemic hyperinsulinemic clamp on healthy volunteers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None